Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioVie Inc. - Common stock
(NQ:
BIVI
)
1.240
+0.010 (+0.81%)
Streaming Delayed Price
Updated: 3:59 PM EST, Jan 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioVie Inc. - Common stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
BioVie Inc. and iRemedy Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
March 24, 2023
Via
ACCESSWIRE
Biovie Inc. (NASDAQ: BIVI) is a Stock Spotlight on 3/22
March 22, 2023
Via
Investor Brand Network
Biovie Inc. (NASDAQ: BIVI) is a Stock Spotlight on 3/17
March 17, 2023
Via
Investor Brand Network
Biovie Inc. (NASDAQ: BIVI) is a Stock Spotlight on 3/16
March 16, 2023
Via
Investor Brand Network
Why Shares of BioVie Jumped This Week
↗
March 10, 2023
BioVie's announcement regarding a phase 2 trial for its lead therapy helped raise the stock's price.
Via
The Motley Fool
BioVie Says Its Parkinson's Candidate Eases Morning 'Rigid Muscles'
↗
March 06, 2023
Via
Benzinga
Why Shares of BioVie Jumped 51.7% in February
↗
March 02, 2023
The company is forging ahead with a phase 3 trial for its lead therapy.
Via
The Motley Fool
Why Shares of BioVie Rose 15.3% in December
↗
January 05, 2023
The biotech announced positive news from a pair of phase 2 clinical trials.
Via
The Motley Fool
Why BioVie Stock Is Soaring Today
↗
December 08, 2022
The more investors learned about BioVie's latest clinical results, the more they liked.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
February 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
February 22, 2023
Via
Benzinga
RedChip CEO Dave Gentry Invited to Join Forbes Business Council
January 25, 2023
Via
ACCESSWIRE
Analyzing BioVie's Short Interest
↗
January 06, 2023
BioVie's (NASDAQ:BIVI) short percent of float has risen 27.02% since its last report. The company recently reported that it has 612 thousand shares sold short, which is 6.77% of all regular shares that...
Via
Benzinga
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
December 29, 2022
Via
ACCESSWIRE
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
January 03, 2023
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.
Via
Benzinga
How Is The Market Feeling About BioVie?
↗
December 21, 2022
BioVie's (NASDAQ:BIVI) short percent of float has risen 67.61% since its last report. The company recently reported that it has 379 thousand shares sold short, which is 5.33% of all regular shares that...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
December 20, 2022
Via
Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
↗
December 20, 2022
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who...
Via
Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
↗
December 20, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Melco, Ardelyx And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
↗
December 19, 2022
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Cosmos Health Inc. (NASDAQ: COSM) shares dipped 37.7% to $14.33 in...
Via
Benzinga
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Cuong Do, President & CEO BioVie Inc.
December 13, 2022
Via
ACCESSWIRE
EXCLUSIVE: Benzinga Moneymaker Series: Top 5 Stocks For Investors To Watch
↗
December 09, 2022
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. The rise of social media and retail traders gave way to countless methods to uncover new information....
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
December 09, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
December 08, 2022
Via
Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
↗
December 09, 2022
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
December 07, 2022
Via
Benzinga
US Stocks Mixed; Dow Rises 50 points
↗
December 07, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 50 points on Wednesday.
Via
Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
↗
December 08, 2022
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Via
Benzinga
Why BioVie's Shares Tumbled Tuesday
↗
December 06, 2022
The clinical-stage biotech released data on its prospective Alzheimer's therapy.
Via
The Motley Fool
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
↗
December 07, 2022
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
